US and World News

Sanofi and Regeneron present more positive data for Dupixent product

Reuters
Reuters
VivaTech conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris

PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product.

The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)

Related News:   Trump Defense Attorney Says Bragg’s Charges Are Really Just 34 ‘Pieces Of Paper’

tagreuters.com2022binary_LYNXMPEI9A06Y-BASEIMAGE


tagreuters.com2022binary_LYNXMPEI9A071-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.